This AlA for corticotropin (ACTH) involves use of a commercially available antiserum and permits measurement of immunoreactive ACTH in unextracted plasma. The assay takes 2.5 days, detects as little as 5 pg/mL of plasma, and is specific: structurally and (or) biosynthetically related peptides do not cross react. Generally, data on dilutions of almost all human plasma specimens produce curves parallel to that for the ACTH reference standard. Values correlate well with those obtained by a well-established but more laborious RIA. We measured immunoreactive ACTH in normal subjects at various times of the day and after modulation of their pituitary-adrenal axis, and in patients with hypo-and hypersecretion of ACTH. We conclude that the full range of immunoreactive ACTH values, which accurately reflect the status of the subject's pituitary-adrenal axis, can be quickly and easily determined in samples of unextracted human plasma.
Orange, NJ 07052) conjugated to bovine serum albumin (BSA, cat. no. A9647; Sigma Chemical Co., St. Louis, MO 63178) by the carbodiimide method (5). Synthetic intact human ACTH and the (1-16)-NH2, (1-18)-NH2, 11-24, and N#{176}-1-acetyl-(1-13)-NH2 (a-melanotropin) fragments of it were gifts of Ciba-Geigy, Ltd., Basal, Switzerland. Synthetic fragments 5-18 and 5-24 were gifts of Dr. D. DeWeid, Rudolf Magnus Institute for Pharmacology, Utrecht, The Netherlands. Human /3-lipotropin and its amino-terminal fragment, y-lipotropin [/3-lipotropin(1-56)], were purified from human pituitary glands in our laboratory (10). Synthetic h/3-lipotropin and (59-89), the former also called "h/3-melanotropin" and the latter "hf3-endorphin," were provided by Ciba-Geigy, Ltd., and Dr. J.
Rivier, The Salk Institute, La Jolla, CA 92138, respectively.
Phosphate-EDTA
buffer. A 63 mmol/L phosphate-EDTA buffer, pH 7.4, was prepared by dissolving 16 .84 g of Na2HPO4-7H2O, 4.74 g of Na2EDTA' 2H2O, and 0.2 g of NaN3 in deionized water, adjusting the pH to 7.4 with 1 mol/L NaOH if necessary, and diluting to 1 L. This buffer was stored at 4#{176}C. RIA buffer. To the phosphate-EDTA buffer was added 1 mL of Triton X-100 (cat. no. 111020; Research Products International Corp., Mount Prospect, IL 60056) and 250 000 kallikrein inhibitory units of aprotinin (Trasylol; FBA Pharmaceuticals, New York, NY 10022) per liter (10). This buffer was also stored at 4 #{176}C.
Bovine serum albumin-RIA buffer. A 35 g/L solution of BSA (cat. no. A9647, Sigma) in phosphate-EDTA buffer was prepared, and 100 g of silicic acid (cat. no. SIL-A-200, Sigma) that had previously been sieved to exclude particles smaller than 100 mesh was added per liter. This suspension was rotated to mix end-over-end for 30 mm at room temperature. The purpose of this procedure is to extract corticotropin and any other contaminating peptides that may interfere in the RIA. The suspension was centrifuged (6000 x g, 10 mm), and the supernatant BSA-RIA buffer was stored at -20 #{176}C.
RIA diluent. Diluent, used to dilute the standard and plasma samples for RIA, was prepared by adding, per liter, 1 mL of Triton X-100 and 250 000 kallikrein inhibitory units of aprotimn to the BSA-RIA buffer.
Standards.
About 0.5 mg of human ACTH was dissolved in 10 mmol/L HC1,and the concentration was adjusted to 1 g/L, as determined spectrophotometrically (11). Two-microliter aliquots containing 2 tg of ACTH were pipetted into 1.5-mL conical polypropylene tubes (cat. no. until used for iodination. The remaining ACTH was diluted to 1 mg/L with RIA buffer and stored in 100-pL (100-ng) aliquots at -70 #{176}C until used as reference standard. The ACTH analogs and other peptides were similarly diluted, aliquoted, and stored frozen.
Procedures
Samples. Blood was collected in a chilled syringe and enough was transferred to fill either a 5-or 10-mL Vacuminer Tube (Becton, Dickinson and Co., Rutherford, NJ 07070) containing Na2EDTA. Plasma was prepared and stored as previously described (5) . ACTH was extracted from some plasma samples with silicic acid before RIA (5).
Radioiodination.
ACTH was labeled with 125j and punfled as previously described (5) with two exceptions: (a) the 0.9 x 57 cm column of Sephadex G-50 fine resin (cat. no. 17-0042-02; Pharmacia Fine Chemicals, Piscataway, NJ 08854) that was used to separate '251-labeled ACTH from 125! after iodination was equilibrated and developed in RIA buffer; this same column was extensively washed with RIA buffer and was used to repurify the labeled ACTH immediately before each assay; and (b) BSA was omitted from the purification procedure.
Assay procedure. was diluted 30-fold with RIA buffer, 100 L was added to each tube, the racks were shaken, and the incubation was continued for 3 h under the same conditions. To separate bound from free ACTH, we added 1.6 mL of ice-cold phosphate-EDTA buffer containing 20 mg of BSA per milliliter, then immediately centrifuged (6000 x g, 20 mm) the tubes. Immediately after centrifugation, each centrifuge carrier, which contained 35 assay tubes, was covered with stainless steel wire mesh and inverted to drain the supernates. Keeping the wire mesh inverted, we pressed it against eight layers of paper towel to blot each tube simultaneously. The tubes, which contained the antibody-bound 1251-labeled human ACTH pellets, were counted for 5 mm in a gammascintillation spectrometer (Model no. 4/600; Micromedic Systems, Horsham, PA 19044). (Figure 1 ).
Results

Radioimmunoassay Characteristics
Sensitivity.
Assay sensitivity can often be improved by using a two-stage RIA protocol, delaying addition of labeled tracer antigen to the system (12) . The sensitivity ofour twostage, two-day RIA procedure was fourfold that of a singlestage, one-day assay, the only changes being incubation of unlabeled standards and samples with the antiserum for one day prior to adding the labeled tracer, followed by incubation for another day prior to separation. With the two-stage RIA, 10% of the labeled tracer was displaced (ED10) by only 0.5 pg (0.11 fmol) of unlabeled ACTH per tube, the ED50 being 3 pg (0.66 fmol) per tube and the ED50 9 pg (2fmol) per tube ( Figure 2 ). The routine level of the detection ofplasma IR-ACTH with thetwo-stage, two-day RIA was 5-10 pg/mL (1.1-2.2 pmol/L).
The one-day, single-stage assay protocol can be used to obtain results more rapidly if less sensitivity is acceptable. Antibody binding of labeled antigen is almost at equilibrium by 24 h (Figure 1 ). Thus, a single-stage assay, in which rsIlabeled ACTH in 100 pL of RIA diluent is added at the beginning of the incubation, can be performed with the same dilution offirst antibody. We add the second antibody after 22-24 h, incubate for another 3 h, and separate bound from free labeled antigen as in the two-stage assay. There was only a slight decrease inB0, but there was a significant loss in sensitivity: the ED10 increased to about 2 pg/tube, and the ED50 and ED50 were proportionately increased to 15 and 40 pg/tube, respectively. Almost the same sensitivity (ED10, ED50, and ED50 of 2.5, 15, and 50 pg/tube, respectively) can be achieved by an even more rapid protocol inwhich the second antiserum is added at the beginning of the Precision. Intra-and interassay variation was determined at three concentrations of plasma IR-ACTH. The intraassay coefficient of variation, determined by measuring the IR-ACTH in five replicates of three separate plasma samples in a single assay, was 7.3, 4.6, and 13.2% when the respective plasma concentrations of IR-ACTH were 15, 60, and 125 pg/mL. The interassay coefficient of variation, determined by measuring the JR-ACm in the same three samples of plasma in 10 successive assays, was 9.2,8.6, and 12.4%, respectively.
DURATION OF INCUBATION-days
Specificity. Hormones structurally and (or) biosynthetically related to ACTH (i.e., the lipotropins and melanotropins) all reacted less than 0.5% as much as the ACTH standard with the IgG-ACTH-1 antiserum. The antiserum is directed toward the steroidogemc amino-terminal (1-18) sequence of the ACTH molecule (13) ; the minimum sequence that we have defined as being required for complete immunoreactivity is ACTH(5-18) (Figure 2 ). This sequence is identical in all species thus far investigated. Thus, this RIA should be capable of measuring plasma or tissue ACTH concentrations not only in humans, but in many other species. 
Comparison Studies
Correlation with an established ACTH RIA. Initially, Lack of physiologic correlation due to plasma interference in the ACTH RIA. As more individual plasmas were studied, it became apparent that sampls from individuals expected to have low concentrations of plasma IR-ACTH, such as normal subjects whose ACTH secretion had been suppressed by administration of dexamethasone, frequently appeared to contain significant amounts of IR-ACTh (Figure 4) . Because we had not encountered this problem .when ACTH was extracted from similar plasma samples before measurement by RIA (5), we assumed that nonspecific inhibition of antigen-antibody binding by plasma components contributed to the apparent IR-ACTH content of the samples. Three lines of evidence supported this hypothesis: (a) "hormone-free plasma," prepared as the 6000 x g supernate of plasma from which the hormone had been removed by adsorption to silicic acid one to four times (5), consistently contained significant amounts of"IR-ACTH" ( Figure 5); (b) the slopes of the displacement curves generated by serial dilutions of "hormone-free plasma" were consistently not parallel to that of the standard (Figure 5 ), indicating that the component(s) causing the displacement of I-labeled human ACTH from antibody was not immunologically identical to ACTH; and (c) each undiluted sample of "hormone-free plasma" inhibited antigen-antibody binding by a relatively constant amount, 24 ± 1.4% (mean ± SEM) ( Figure 5) , irrespective of the original IR-ACTH content of the plasma.
Source of plasma interference in the ACTH RIA. The "IR-ACTH" content of"hormone-free plasma" appeared to be the result of interference with antigen-antibody binding by plasma proteins, because most of the "IR-ACTH" in such samples eluted with the higher-Mr plasma proteins during gel ifitration, rather than with authentic human ATCH ( Figure 6 ). This "IR-ACTH" was not decreased by repeated Minimizing plasma protein interference in theACTHRIA. Because the addition of unextracted plasma to the assay resulted in relatively constant nonspecific displacement of 1251..labeled human ACTH from antibody, we anticipated that this artifact could be minimized by including in the assay appropriate concentrations of "hormone-free plasma," so that the binding in all assay tubes would be similarly reduced. However, use of "hormone-free plasma" is not practical in a high-volume RIA laboratory, because of the difficulty and expense in procuring sufficient quantities of human plasma. Therefore, we evaluated preparations of several readily available animal serum proteins, among them solutions of BSA roughly equivalent in protein concentration to that of normal human plasma. At this concentra- ACTH or PLASMA -pg or pL/tube Ag. 5. Plasma IR-ACTH concentrationsin hormone-free plasma' (the 6000 x g supemate of plasma after adsorption with silicic acid) from nine normal subjects
The "hormone-free plasma" samples were assayed undiluted and diluted threefold with AlA buffer,which was also used to dilutethe ACTH standard. Each point represents the mean of three determinations. over the whole range of the RIA standard curve (Figure 8) . We therefore considered this protein solution to be a suitable diluent for samples and standard in the unextracted plasma ACTH RIA. plasma specimens (Figure 9) . The values covered the normal range of plasma IR-ACTH concentrations, and there was good correlation between the results obtained by both methods, including those results in the low normal range (Figure 9 ). Very occasionally, some patients' unextracted plasma still generated competitive binding curves that were less steep than that of standard ACTH. This property was characteristic of certain individuals, such that curves generated by plasma specimens obtained from them on several occasionsmany days to several weeks apart were always parallel to each other, but not parallel to the standard. Subjects whose plasma exhibited this property included both normal individuals and patients. Extracted samples of the same plasma specimens almost always generated parallel curves in the RIA for ACTH, indicating that it was not a differencein the structure of the hormone that caused this phenomenon. The artifact can be detected by assaying more than one dilution of plasma and can be corrected, when necessary, by extracting ACTH from the plasma of such subjects before assay (5).
Physiologic Correlations
The data shown in Figure 10 represent only a very small fraction of our overall experience with this RIA. None of the results from those very occasional subjects or patients whose plasma generated nonparallel displacement curves is included.
Norma! subjects. study reported elsewhere (16) . A wider range of plasma IR-ACTH, 8-79 pg/mL, was found between 0700 and 0800 h in a separate group of nine volunteers whose activities were unrestricted before blood collection. Six hours after these nine subjects were given 0.5 mg of dexamethasone intravenously at 0800 h, plasmaIR-ACTH in each had fallento undetectable concentrations EXTRACTED PLASMA IR-ACTH -pg/mL Normal subjects were studied as descnbed in the text The patients with pituitary ACTH-dependent Cushing'ssyndromewere studied 1 h afterfallingasleep;the other patients were sampled between 0800 and0900 h (i.e., <5 pg/mL) at 1400 h. Plasma IR-ACTH determined between 1600 and 1700 h in a third group of 50 normal volunteers who had been supine for at least 45 mm before sampling (17) ranged from 7 to3Op.
Plasma concentrations of IR-ACTH
Thirty to 45 miii after eight of these subjects received intravenous insulin (0.15 units/kg body wt) to induce hypoglycemia (plasma glucose 400 mg/L), their plasma IR-ACTH had increased to 135-370 pg/mL. A fourth group of eight normal volunteers, who were hospitalized as part of previous study (12) and had been recumbent for at least 1 h before sampling, all had plasma IR-ACTH concentrations of 10 pg/mL or less at midnight.
Patients
with pituita?y or adrenal disorders.
Eight patients with untreated pituitary ACTH-dependent Cushing's syndrome, or Cushing's disease, had plasma JR-ACm concentrations of 23-95 pg/mL when sampled 1 h after falling asleep. Only one of six patients with Cushing's syndrome caused by a cortisol-producing adrenal tumor had detectable plasma IR-ACTH, whereas the concentrations in four patients whose syndrome was caused by ectopic production of ACTH ranged from 125to800pg/mL. Adrenal insufficiency and Nelson's syndrome were both associated with high concentrations of plasma LR-ACTH, up to 7250 pg/mL. Plasma IR-ACTH was relatively low (10-20 pg/mL) and was unresponsive to insulin-induced hypoglycemia in two patients with hypopituitarism.
Discussion
RIAs for ACTH have not been more widely applied primarily because, along with a handful of other RIAs, this assay has remained very difficult to perform. The normal concentrations of ATCH that circulate in plasma are very low, about 2-15 pmolJL, lower than the sensitivity of the available assays for ACTI{. Consequently, virtually all RIAs forACTH (1) (2) (3) (4) (5) have required priorextraction and concentration of the hormone from plasmaand (or) incubation times of four to seven days to achieve sensitivity similar to that of the present assay. One possible exception (6) involved an antiserum that was never made available to others.
The present RIA method overcomes these technical difficulties. A commercially available antiserum of unique sensitivity and requisite specificity is used and low-normal to subnormal concentrations of IR-ACTH can be measured in 5-18), but not at all with ACTH(11-24) . Thus, full reactivity requires both a part ofthecommon ACTH(5-10) sequence and a carboxyl-terminal extension of eight residues or less. a-Melanotropin has an identical tripeptide extension, but the final residue is amidated; none of the other peptides has any sequence in common with ACTH (11) (12) (13) (14) (15) (16) (17) (18) . Presumably, the affinity of the antibody for this region of the ACTH molecule confers its specificity for ACTH alone. Furthermore, because the antibody is directed at the ACTH (5-18) One problemdid arise during the development of this RIA: unextracted plasma expected to contain low concentraoreofACTH (e.g., from patients withCushing's syndrome Jue to adrenal tumor, patients with panhypopituitarism, and normal subjects administered dexamethasone) frequently had decreased bound label and were, therefore, interpreted as containing significant concentrations of IR-ACTH. We found that this was an artifact caused by nonspecific inhibition of antigen-antibody interaction by high-Mr components in plasma, presumably proteins; to correct this, we diluted standard hormone and plasma specimens with RIA diluent containing 35 g of BSA per liter, from which endogenous ACTH and (or) other unidentified contaminants had been removed by adsorption to silicic acid. When we used this diluent, most unextracted plasma specimens generated parallel competitive-binding curves, and their plasma IR-ACTH concentrations correlated well with those determined by more laborious RIA of silicic acid extracts ofthesame plasma specimens.
As determined with this method, plasma concentrations of JR-ACT!! in a variety of conditions have been similar to those previously reported (1-6), and thus far our data have accurately reflected the status of the subjects' pituitaryadrenal axis. Normal subjects receiving dexamethasone had undetectable plasma JR-ACT!! (<5 pg/mL); plasma IR-ACTH innormalsubjects tendedtobe less atmidnight than earlier in the day; midnight concentrations of plasma IR-ACTH in eightpatients with Cushing's disease exceeded those of eight normal subjects studied at the same hour; in patients with Cushing's syndrome due to autonomous cortisol production by an adrenal tumor, plasma IR-ACTH was invariably low and was undetectable in five of six cases; four patients with Cushing's syndrome due to ectopic production of ACTH had markedly increased concentrations of plasma JR-ACm, as did four patients with untreated Addison's disease and two patients with Nelson's syndrome; and although low concentrations of plasma IR-ACTH were detected in two patients with hypopituitarism, the values did not increase during insulin-induced hypoglycemia, as they did in normal subjects.
Very occasional subjects' unextracted plasma still reproducibly generated nonparallel binding curves. This did not appear tobe caused by structural alterations in their ACTh, because extracts of plasma did not cause this phenomenon and could be used to quanti1r more correctly their concentrations of JR-ACT!!.
With this RIA method, plasma ACTH concentrations can
